Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-03-17

Clinical Trial Update: Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

A safety study evaluating sorafenib with androgen deprivation and radiotherapy for prostate cancer was terminated with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sorafenib (Sorafenib)

Snippet

Sponsor: Beth Israel Medical Center | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2015-03-17